Single-cell characterization of anti-LAG3+anti-PD1 treatment in melanoma patients

ABSTRACT: In this study, we analyzed the lymphocyte response to anti-LAG3+anti-PD1 treatment (relatilimab+nivolumab, phase I, NCT01968109) in prior and 4- and 12-week posttherapy blood samples from 40 metastatic melanoma patients using scRNA+TCRαβ-seq, flow cytometry, TCRβ-seq, and serum protein profiling together with ex vivo functional validations.

PROVIDER: EGAS00001005580 | EGA |

REPOSITORIES: EGA